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Genetic Analysis in iPSC: Results 
and Lessons from the ForIPS 
Consortium
Bernt Popp  1, Mandy Krumbiegel1, Janina Grosch2, Annika Sommer3, Steffen Uebe1, 
Zacharias Kohl  2, Sonja Plötz2, Michaela Farrell3, Udo Trautmann1, Cornelia Kraus1, 
Arif B. Ekici  1, Reza Asadollahi  5, Martin Regensburger  3, Katharina Günther4, 
Anita Rauch5, Frank Edenhofer4, Jürgen Winkler2, Beate Winner3 & André Reis  1
Genetic integrity of induced pluripotent stem cells (iPSCs) is essential for their validity as disease models 
and for potential therapeutic use. We describe the comprehensive analysis in the ForIPS consortium: an 
iPSC collection from donors with neurological diseases and healthy controls. Characterization included 
pluripotency confirmation, fingerprinting, conventional and molecular karyotyping in all lines. In the 
majority, somatic copy number variants (CNVs) were identified. A subset with available matched donor 
DNA was selected for comparative exome sequencing. We identified single nucleotide variants (SNVs) 
at different allelic frequencies in each clone with high variability in mutational load. Low frequencies 
of variants in parental fibroblasts highlight the importance of germline samples. Somatic variant 
number was independent from reprogramming, cell type and passage. Comparison with disease genes 
and prediction scores suggest biological relevance for some variants. We show that high-throughput 
sequencing has value beyond SNV detection and the requirement to individually evaluate each clone.
Genetic variants influence cellular mechanisms, thus leading to specific phenotypic presentations in the organ-
ism, both in rare and common disease. Neurological disorders like Parkinson’s disease (PD) typically comprise 
both rare and common genetic risk variants with large and small effect sizes, respectively. Studying the patho-
mechanism in patient cells is often limited because the disease relevant tissues are not accessible. Human embry-
onic stem cells (ESC) can be differentiated into cells from all three germ layers (endoderm, mesoderm, ectoderm) 
but pose legal and ethical issues. In contrast, induced pluripotent stem cells (iPSCs) can be derived from adult 
tissues using exogenous expression of four transcription factors (POU5F1, SOX2, KLF4, MYC) and can be differ-
entiated into somatic cells in vitro1–3. Human iPSCs promise not only easy access to cells for scientists interested 
in disease modelling but also personalized medicine for patients affected by rare diseases.
While different protocols (non-/integrating viral, non-integrating non-/viral) for the generation of iPSC lines 
have been established, quality control (QC) during reprogramming, differentiation and culturing steps remains 
an area of active development4. Loss of genetic integrity as a source of variability in iPSCs5 and in therefrom 
derived cells is a possible confounder compromising their validity as disease models. Certain genetic variants 
could be associated with increased risk of cancer or dysfunction when using these cells for regenerative therapeu-
tic interventions. Indeed, tumorigenicity has been reported in transplanted stem cells6, and a recently published 
clinical trial using autologous iPSC derived retinal cells7 was temporarily halted due to concerns of tumorigenic 
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potential. Finally, somatic TP53 mutations previously identified in tumors were found in iPSC lines by applying 
exome sequencing8. Taken together, a detailed characterization of genetic differences between donor and derived 
cells should be a central part of any iPSC-QC pipeline to ensure validity and safety.
Several groups and large consortia have studied the origin, quality and quantity of genetic variants found in 
iPSCs but absent from the donor’s germline5,9–11. There is high variability in the methods used and the results 
reported. Also, the nomenclature for variants of different origin is inconsistent and often derives from research 
on cancer and developmental disorders.
Aneuploidies affecting the number of whole chromosomes in a cell are widely accepted as undesirable aber-
rations with potentially large effects in cells. Hence, conventional karyotyping is a standard QC measure used 
to detect these abnormalities in iPSCs. Similarly, somatic copy number variants (CNVs) like microdeletions 
and –duplications, typically comprising several genes or regulatory elements, are unfavorable. Although CNVs 
can be detected using chromosomal microarrays (CMA), this technique is not yet generally used to investigate 
iPSCs. High-throughput sequencing methods (“next-generation sequencing”; NGS) have enabled the exome and 
genome wide detection of single nucleotide variants (SNVs/indels). Several reports have shown considerable load 
of SNVs in iPSC12–15.
Here, we describe the ForIPS stem cell biobank resource, a national consortium with the primary goal to 
establish iPSC technologies to study molecular and cellular mechanisms involved in neurological disorders like 
PD. We present our approach to a stringent genetic workup, including conventional karyotyping, genetic finger-
printing and CMA in all cell samples. We report results of high coverage exome sequencing in a subset of this 
cohort selected to establish a suitable pipeline for iPSCs.
Results
Characteristics of individuals included and iPSCs generated in the ForIPS biobank resource. 
The ForIPS study (Fig. 1A) included 23 individuals (11 females and 12 males) of which 9 individuals (5 females, 4 
males) were healthy controls without any neurologic disease (CT), 14 were patients affected (AP) by one of three 
neurological diseases: PD (1 female, 8 males), hereditary spastic paraplegia (HSP, SPG11 gene, OMIM #604360 
and *610844; 3 females), monogenic intellectual disability (ID; 2 females). The age at donation of fibroblasts 
ranged from 22 to 73 years (y) with a median of 45y. In CTs the age range was 23 to 70y with a median of 45y, and 
in APs the age range was 22 to 73y with a median of 45.5y. The oldest subgroup included individuals with PD 
(age range 36 to 73y, median 54y). Nine individuals were members of 4 families: “J2C” and “1JF” are father and 
son, “88H”, “O3H” and “82A” are siblings, “PT1” and “CT1” are siblings and “55O” and “G7G” also are siblings 
(Fig. 1B; see also Fig. S1 and File S1).
In the iPSC lines derived from fibroblasts, pluripotency was confirmed by positive staining for POU5F1 and 
NANOG for all iPSC lines, and fluorescence-activated cell scanning (FACS) analysis for TRA-1-60 was positive 
for >90% of the cells in each line (Fig. S1). All fibroblasts and iPSC lines generated in the ForIPS consortium, 
which passed these pluripotency criteria were sent to genetic QC. A cell suspension from each culture was sub-
ject to an initial integrity screening (Fig. 1A: “step 1”) using conventional karyotyping to detect aneuploidies 
and larger chromosomal aberrations. In this first QC step ~15% of iPSC cultures were discarded due to signifi-
cant chromosomal aberrations (Fig. S1 and File S2). In addition, DNA-based fingerprinting (PowerPlex assay) 
was employed to verify sample identity in most samples or was replaced by CMA based fingerprinting (Fig. S1; 
File S2). Three iPSC lines did not match DNA from donor fibroblasts and were excluded from further analysis. 
For the remaining lines, fingerprinting matched with the respective fibroblast and with the reported donor sex. 
Samples which passed the first QC step were included into our subsequent studies (Fig. 1B; File S1). This group 
included 72 primary iPSC lines with a median number of 3 iPSC lines per individual (range 2 to 6) and a median 
passage number of 14 at time of analysis (range 2 to 39). Forty-nine of these iPSC lines were generated by using 
integrating retroviral reprogramming (RiPSC) and 23 lines using non-integrating Sendai reprogramming (SiPSC) 
Yamanaka transcription factors2,16. RiPSC had a higher median passage number of 15 (range 2 to 39) at analysis 
compared to 5 for SiPSCs (range 3 to 15). Four RiPSC lines from two individuals (“AY6”, “82A”) were differenti-
ated into midbrain neuronal progenitor cells1 (NPCs) and had a median passage number of 7.5 (range 5 to 13). 
To investigate the relationship between passage number and somatic variants, four RiPSC lines from the same 
individuals were cultured to higher passages of 30 and 40, respectively.
Detection of somatic CNVs by high density SNP-based CMA. In a second analysis step all study 
samples passing step 1 (23 fibroblast cultures, 49 RiPSCs, 4 hereof derived NPCs, 4 RiPSCs at passages 30 and 40, 
and 23 SiPSCs) were screened for CNVs with a high-resolution, single-nucleotide polymorphism (SNP)-based 
chromosomal microarray (CMA). We used the Affymetrix CytoScan HD array as it is an established and reliable 
tool in routine germline diagnostics at our Center for Rare Diseases17,18. Array QC measures passed manufacturer 
recommended thresholds in 97.2% of analyzed samples (105/108). The CMA data for the other three samples 
were only marginally below these thresholds and after manual review considered to be of sufficiently good quality 
(File S2; Fig. S3). The CMA for each analyzed culture was visually screened by a trained expert (M.K.) for aberra-
tions ≥100 kilobases (kb) and absent from donor fibroblasts (Supplementary information). We identified a total 
of 93 sub-chromosomal CNVs with sizes ranging from 100 kb to 6.4 Mb (megabases) including 48 deletions and 
45 duplications (Fig. 2). Most aberrations (91/93) were smaller than the lower detection limit of 5 to 10 Mb typi-
cally assumed for G-banded karyotyping19. In addition, we observed trisomy of chromosome 12 in three RiPSC 
cultures (“i1JF-R1-002”, “i1E4-R1-012”, “i1E4-R1-016”), twice only present in a sub-population of cells. In the 
SiPSC line “CT1-S1-010” we detected a copy number gain affecting all terminal markers on chromosome 17q. 
Despite its size of 5.9 Mb this CNV was not detectable by conventional karyotyping. The chromosomal position 
indicated the possibility of an unbalanced translocation which was confirmed by fluorescence in situ hybrid-
ization (FISH) analysis as a 14p/17q unbalanced translocation probably of somatic origin (Fig. 3A,B). While 
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karyotyping and CNV analysis based on intensity data of chromosome 9 showed unremarkable results in SiPSC 
line “i82A-S1-004”, SNP allele peak distribution uncovered a copy neutral allelic imbalance on the long arm of 
chromosome 9 indicating a ~30% sub-clonal cell population carrying a partial uniparental isodisomy (Figs 3C 
and S2).
Next, we compared RiPSCs and SiPSCs to reveal method-specific differences: 58 somatic CNVs were detected 
in 34 of 49 (69.4%) RiPSCs, and 35 somatic CNVs in 17 of 23 (73.9%) SiPSCs. Only 15 of the RiPSCs (30.6%) and 
six SiPSCs (26.1%) showed no somatic CNVs. CNV size varied between 106 kb and 6.4 Mb in RiPSC, and between 
100 kb and 5.9 Mb in SiPSC lines. The number of affected genes based on Genbank annotation varied between 
0 and 139 with a higher variability in RiPSC lines. Three aberrations in RiPSC contained no genes, whereas all 
aberrations in SiPSC included genes. Our data showed no significant differences regarding number, size and 
gene content of somatic CNVs between RiPSC and SiPSC clones, indicating a comparable genetic cell quality 
(Fig. 2A–C). Also, there was no significant difference between sexes, relatives- and affected-status confounding 
the analyses (Fig. S3).
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Figure 1. Schematic summary of the study and nomenclature of genetic aberrations. (A) Culturing and QC 
steps. Step 1: genetic fingerprinting and conventional karyotyping. Step 2: high-resolution CMA. Step 3: exome 
sequencing. (B) Graph showing the age distribution (x-axis) and phenotype of all donors. Fibroblast cultures are 
plotted as symbols (white = unrelated individuals; blue, red, green = related individuals) on the grey timeline 
(male = square; female = circle). The three-letter codes in these symbols represent each individual’s donor IDs 
(see also Fig. S1C). The passage of the derived RiPSC (above) and SiPSC (below) cultures are plotted as circles 
connected to the respective fibroblast (y-axis; scattered for visualization). Derived NPCs are connected to 
the RiPSC they originated from. Red bars below the fibroblast symbols mark individuals with PBLs available 
selected for exome sequencing. See also File S1 for additional information. (C) Standardized nomenclature 
for variants/aberrations depending on the cell they arose in. The scheme compares the evolutionary history 
of a cancer cell (box “selection”) which is subject to a strong selective pressure with that of a cultured cell (box 
“genetic drift”) which is mainly subject to random genetic drift.
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In four RiPSC clones cultured to higher passages we could not observe any CNV differences during passaging 
(File S3), and the average somatic CNV number aggregated per individual showed no correlation with passage 
number (Fig. 2D). Additionally, the somatic CNV count was not correlating with the probands’ age at the time 
of biopsy (Fig. 2E).
NPCs showed the same CNVs detected in the corresponding RiPSC clones indicating genetic stability during 
differentiation (Fig. 2A–C; File S3). In the NPC culture derived from the RiPSC “i82A-R1-001” we observed 
two previously fixed CNVs which had lower intensities in the NPC compatible with a ~50% sub-population: A 
somatic deletion affecting the DLG2 gene and a deletion affecting the genes VCX and PNPLA4 (Fig. S2). This 
observation shows that the RiPSC culture was initially oligoclonal, and points to either selective pressure of cul-
ture conditions or random genetic drift introduced by manual picking as the cause of the allelic shift in this NPC 
culture.
Although the identified somatic CNVs were scattered throughout the genome (Fig. 2F), we detected three 
regions representing possible, specific hotspots. First, two overlapping deletions affecting the CTNNA3 gene 
in 10q21.3 were identified in a RiPSC clone of individuals “88H” and “O3H”, respectively (Fig. 3D, File S3). 
Second, three aberrations within the DLG2 gene were detected: two overlapping deletions in the iPSC clones 
“i82A-R1-001” and “i82A-R1-002” of “82A” as well as a duplication in the SiPSC clone “iK22-S1-001” of “K22” 
(Fig. S2). Many smaller and overlapping aberrations in both regions were observed in healthy control individu-
als (Database of Genomic Variants20). Furthermore, a mosaic gain in 20q11.21 including the BCL2L1 gene was 
revealed in two different RiPSC clones of “PX7” and one clone of “1JF”.
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Figure 2. Summary of somatic CNVs identified in iPSC cultures by chromosomal microarray analysis (CMA). 
Box- and scatterplots for (A) the total number of somatic CNVs detected per analyzed cell culture sample 
(grey dots), (B) the genomic length (hg19) in kb of all detected somatic CNVs (C) and the number of affected 
genes (GenBank) within identified somatic CNVs (red dots = copy number loss, blue dots = copy number 
gain). SiPSC and RiPSC are separated by a grey dashed line. In the NPCs derived from the RiPSCs no new 
somatic CNVs were identified. No significant differences regarding number, size and gene content of somatic 
CNVs between RiPSC (n = 49) and SiPSC clones (n = 23) were detected (two sided Wilcoxon signed-rank 
test). Aneuploidies are not included and CNV outliers (one in SiPSC and one in RiPSC) sized over 5000 kb 
are excluded from panels B and C. (D) The average number of CNVs in all iPSCs grouped per individual and 
passage number plotted vs. the passage number. The dashed blue line represents the linear regression model 
fit (R2 = 0.021, p-value = 0.264). (E) The average number of CNVs in all iPSC grouped per individual plotted 
vs. the donor age in years at biopsy. The dashed blue line represents the linear regression model fit (R2 = 0.049, 
p-value = 0.309). Diamonds in D and E mark the respective average CNV count and are intersected by a 
standard error bar where applicable. (F) Circos plot showing the genomic (hg19) distribution of somatic CNVs 
in RiPSC (orange) and SiPSC (blue) clones. NS, not significant.
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Exome sequencing comparing iPSC and germline donor material to detect SNVs/indels. We 
selected a subset of samples for comparative exome sequencing with following inclusion criteria: (1) Availability 
of a germline DNA sample of the donor (blood) which was not a direct progenitor of the cultured cells (fibro-
blasts). (2) Availability of SiPSC, RiPSC and differentiated NPC lines of the same donor. (3) Access to higher 
passage samples of the lines. (4) Different affected status, age and sex. As the individuals “AY6”, “PX7”, “88H” and 
“82A” met these criteria, we selected a total of 34 samples (4 blood, 4 fibroblast, 8 RiPSC, 4 RiSPC passage 30, 4 
RiSPSC passage 40, 6 SiPSC, 4 NPC). Exome sequencing on an Illumina HiSeq2500 machine and standard pre-
processing resulted in aligned BAM files (Supplementary information) with a median on-target coverage of 163× 
(range 117x to 264x) and ≥95% of the exome target being covered by at least 20 reads (File S2).
Based on an initial feasibility test run with six exomes (Files S1 and S4; Fig. S4; Supplementary information) 
and previous experience from pooled21 and somatic variant calling22, we used the freebayes software23, which 
simultaneously calls all classes of small nucleotide variants (SNVs = single nucleotide variants, MNPs = multiple 
nucleotide polymorphisms, indels = small insertions/deletions; when not specifically stated we use the term SNV/
indel for all classes of small variants). All 34 exome samples were called together with 53 in-house controls from 
the same machine runs with freebayes and resulting variants were annotated with SnpEff24. From here on we 
describe somatic variants obtained after applying hard filters to exclude variants with read evidence in the blood 
samples (Supplementary information; File S4). We considered resulting variants with alternate allele fractions 
(AF) ≥30% as fixed somatic and variants with AF <30% as low frequency somatic variants (File S4 and Fig. S4). 
We identified a median of 38 fixed (minimum 17, maximum 256) and 1651 low frequency (minimum 739, maxi-
mum 3988) somatic SNVs/indels per sample in the coding target regions. We only report the results for the fixed 
variants and did not perform orthogonal validation (e.g. deep amplicon sequencing or digital PCR) for the low 
frequency somatic variants (see Fig. S4) as previously analyzed by others13.
In analogy to the CNV analysis, we investigated SiPSC, RiPSC and NPC exome data for reprogramming or 
differentiation specific effects. No significant differences were detected for somatic SNV/indel numbers between 
RiPSC and SiPSC clones or between RiPSC and their derived NPCs (Fig. 4A,B). Notably, the variance was higher 
for RiPSC (Fig. 4A), an effect resulting from specific cultures (compare Fig. 5A,B) with a much higher variant 
load.
Like for CNVs, we found no correlation between somatic SNV/indel variant load and passage number 
(Fig. 4C). In contrast to the CNV analysis, the somatic SNV/indel count aggregated per individual showed a 
Figure 3. Examples of CNVs detected by SNP-based CMA. (A) Copy number analysis identified a 
chromosome 17q terminal gain not detectable with conventional karyotyping in the SiPSC line “CT1-S1-
010”. (B) FISH analysis showing the unbalanced translocation 14p/17q in this clone (left = metaphase, 
right = interphase). (C) Conventional karyotyping and copy number analysis of chromosome 9 of the 
SiPSC line “i82A-S1-004” revealed unremarkable results (Log2Ratio top), but SNP allele peak distribution 
(xAllelePeaks bottom) uncovered a copy neutral allelic imbalance on the long arm of chromosome 9 (4 bands) 
while the short arm (left) shows normal allelic distribution (3 bands) (see also Fig. S2). (D) Two independent 
overlapping intragenic deletions in the CTNNA3 gene detected in the RiPSC lines “i88H-R1-001” (green 
bottom) and “iO3H-R1-001” (blue bottom) and absent from their fibroblast cultures “f88H-X-001” (green top) 
and “iO3H-X-001” (blue top).
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strong positive correlation with the probands’ age at the time of biopsy (Fig. 4D). However, this observation is 
influenced by above mentioned iPSC cultures from older donors (Fig. 5).
Next, we analyzed specific properties of the identified somatic SNVs/indels. Variants predicted to have 
a moderate impact on gene function (mainly missense variants) represent the largest proportion of identified 
somatic variants (range 35% to 69%) per sample (Fig. 5A). In most iPSC samples, somatic variants were mainly 
SNVs, with only a small portion of indels and MNPs identified. However, four samples showed an unusual high 
Figure 4. Summary of somatic SNVs/indels identified in iPSC cultures by exome sequencing. (A) Box- and 
scatterplot comparing the total number of fixed somatic SNVs/indels in independently reprogrammed SiPSC 
(n = 6) and RiPSCs (n = 8) from four donors (“82A” = grey, “88H” = orange, “AY6” = blue, “PX7” = green). 
(B) Box- and scatterplot comparing the total number of fixed somatic variants in RiPSC and derived NPCs 
from donors “82A” (grey) and “AY6” (blue). No significant differences were detected neither for somatic SNV/
indel numbers between RiPSC and SiPSC clones nor between RiPSC and their derived NPCs (two sided 
Wilcoxon signed-rank test). Certain cultures have a much higher variant load (“82A” = grey, “88H” = orange). 
NPCs have the same variant profile as their progenitor cells. (C) Number of variants in four RiPSC lines 
(“i82A-R1-002” = grey, “i82A-R1-001” = yellow, “iAY6-R1-003” = blue, “iAY6-R1-004” = red) from donors 
“82A” and “AY6” cultured to higher passages vs. passage number. Diamonds mark the respective average SNV/
indel count grouped by cell culture passage number (low passage numbers between 7 and 15 are considered 
as one group) intersected by a standard error bar. Dashed blue line represents the linear regression model fit 
using the actual passage number of the cells in the low group and the average of passage 30 and 40 (R2 = 0.036, 
p-value = 0.718). Note again the high spread influenced by the two cultures from individual “82A”. (D) The 
number of variants in all iPSC lines (RiPSC = ocher and SiPSC = lilac) from the four donors (n = 4 for “82A” 
and “88H”, n = 3 for “AY6” and “PX7”) plotted vs. the donor age. Diamonds mark the respective average SNV/
indel count grouped by donor intersected by a standard error bar. Dashed blue line represents the linear 
regression model fit (R2 = 0.976, p-value = 0.012). NS, not significant.
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proportion of MNPs (Fig. 5B). A closer examination of these samples (File S4) showed that the MNPs are mainly 
CC > TT dinucleotide mutations at dipyrimidines and that they additionally had an increase in C > T/G > A 
transitions (Fig. 5C), both mutational signatures typical for ultraviolet light (UV) irradiation damage25.
Missense variants represented a large part of the identified somatic SNVs in the iPSC cultures. Compared 
to truncating variants their functional interpretation is difficult. We used different computational prediction 
scores to assess their potential pathogenicity. Interestingly the scores obtained for a large portion (CADD: 44,1%, 
M-CAP: 35,0%, REVEL: 12,6%) of these somatic missense SNVs are above the respective recommended patho-
genicity thresholds (Fig. 5D)26–28.
Our exome study design with concurrent sequencing and analysis of blood germline and parental fibroblast 
culture samples enabled us to search for evidence of low frequency somatic variants in fibroblasts due to poly-
clonality (“somatic mosaicism”). While low frequency variants in bulk sequencing data are inherently noisy when 
analyzed alone, prior knowledge of a fixed variant in a descendent culture sample increases the locus specific 
probability of low frequency reads being bona fide somatic variants13,29. Accordingly, the allele fraction (AF) for 
fixed variants in the analyzed iPSC cell cultures followed an expected normal distribution of around 0.5, while 
Figure 5. Mutational characteristics of somatic variants identified in iPSC cultures by exome sequencing. 
Stacked bar chart for the 14 primary RiPSC and SiPSC cultures from 4 individuals with passage numbers 
between 7 and 15 showing the relative number of variants partitioned (A) using SnpEff software annotated 
by variant impact group (HIGH = green, MODERATE = blue, LOW = light green), (B) by variant type 
(SNV = light green, MNP = blue, indel = green) and (C) by mutational subtype (transitions in brownish, 
transversions in greyish turquoise) of the SNVs in each iPSC sample. For A and B absolute variant counts are 
in the bars. (D) Distribution of three different SNV classifier scores represented as violin plots with median 
and quartiles. Red line represents the respective cutoff values (CADD = 20, M-CAP = 0.025, REVEL = 0.5). 
(E) Dot-plot showing the distribution of allele fraction (AF) in the analyzed iPSC cell cultures (x-axis) and 
their corresponding fibroblast culture (y-axis) with each point representing a variant shaded by read coverage 
in the iPSC exome (bright = low, dark = high read coverage at the respective variant position). Dotted vertical 
lines mark the expected AF for a heterozygous fixed variant (0.5) and typical variabilities seen in short read 
sequencing (0.3 to 0.7). (F) Dot-plot showing the relation between read coverage in the analyzed iPSC cultures 
and AF in the corresponding fibroblast culture. Dots are grouped and colored by fibroblast AF (no evidence in 
fibroblast = grey, ≤5.0% = blue, ≤10.0% = orange, >10% = green). The blue line represents the linear regression 
model fit (formula y ~ log(x); R2 = 0.202, p-value < 2.2e–16). The black line represents the theoretical AF in the 
fibroblast culture which is detectable at the respective coverage with a probability of 0.426 (variants with no 
evidence in fibroblast = 546, variants with at least 1 read in fibroblast = 405; 405/(405 + 546) ≈ 0.426) under a 
simple binomial draw model where one read is considered as sufficient evidence in the fibroblast. The red dotted 
line marks read coverage of below 20 where a high sampling variance is expected.
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most of the variants with read evidence in the fibroblasts had a lower AF. In addition, variants at the lower cov-
erage tails had a larger variance in AF influenced by random sampling (Figs 5E and S4). We found a correlation 
between read coverage at somatic variant positions in the iPSC cultures and AF in the corresponding fibroblast 
culture, indicating that somatic variants at low AF can only be found in the fibroblast if sufficient read coverage 
is available. Using a simple binomial draw model, we demonstrate that most variants potentially identifiable as 
being present in the fibroblasts (somatic) indeed do have reads supporting them (Fig. 5F). It is likely that the 
remaining somatic variants are still somatic but only present at a very low AF in the original fibroblast culture and 
that they were just not detectable by bulk exome sequencing13.
Multiple secondary analyses revealed additional iPSC culture characteristics. While the mito-
chondrial genome (“chrM”) is not targeted in most commercial exome designs, exome data still contain consid-
erable mitochondrial coverage due to their high copy number in each cell. We calculated the average coverage 
of chrM (median 263x, minimum 66x, maximum 765x) and normalized it to the coverage of chromosome 1 
(File S5). Fibroblast and R/SiPSC cell cultures showed a significantly higher mitochondrial genome dosage than 
NPC cultures and peripheral blood lymphocytes (PBLs) (Fig. 6A).
Likewise, telomeric genomic regions are not targeted in exome designs but have a high relative coverage in 
the genome. We used two recently described software algorithms (telomerecat30, telomerehunter31) to compute 
the relative telomere content from exome data and to correlate it with the passage numbers. While the estimates 
from both algorithms showed a trend towards less telomere content in higher passages, these results were not 
significant (Fig. 6B). It should be noted that the telomeric content of the 53 in-house exome controls used, when 
correlated with age, also showed a non-significant trend (Fig. S5).
In our initial exome variant calling test in RiPSCs we identified variants in the POU5F1 gene locus absent from 
the parental fibroblast. These were confirmed to be single nucleotide variants from the integrated viral vector 
(Fig. S6). We therefore excluded the genomic regions of all transcription factors used for reprogramming from 
variant calling (Supplementary information). When examining these regions, we noticed the coverage profile 
of the RiPSCs having sudden breaks at the exon-intron boundaries like the profile seen in RNAseq. In contrast, 
fibroblasts and SiPSCs show bell-like shapes over the capture probes, which is typical for capture-based enrich-
ment (Fig. 6C). Our observation indicated multiple genomic integrations (Fig. S6) of the plasmid with intron-free 
transcription factor inserts used for reprogramming of the RiPSC lines.
We wondered whether algorithms for CNV detection from exome data could replace or supplement the 
widely accepted CMA analysis. The CNVkit algorithm32 uses intergenic reads to achieve a more uniform marker 
coverage across the genome. While several CNVs detected previously by CMA were also called from exome data 
using this software, several others were missed (Figs 6D and S6; File S3).
Off-target reads can also be used to check sequencing data for DNA of microorganisms like mycoplasma 
or cross-individual contamination. We used the MinHash based BBSketch algorithm (https://jgi.doe.gov/
data-and-tools/bbtools/) to screen our exome files for cell culture contamination but did not find any evidence 
for high-grade contamination (Fig. S5; File S5). Similarly, we could exclude significant cross-individual contami-
nation, a known problem in iPSC cultures33 using the ContEst34 software (Fig. S5; File S5).
Discussion
Since the discovery of reprogramming methods for somatic cells into pluripotency, the stem cell field has rapidly 
progressed2,3. Precise disease modelling and personalized treatment are some of the promises the iPSC technol-
ogy is beginning to fulfill7. Though advances are increasingly encouraging, there is still considerable heteroge-
neity in research practices4,35. This is especially evident in genetic QC, which in recent years only has received 
systematic attention in large cohorts5,9. Despite a wealth of available experience from pioneering genetic fields 
regarding rare diseases or cancer genetics, the community has not yet agreed upon common minimal standards 
for an iPSC line to be acceptable as a model and to be safe for therapeutic use. Here, we describe the application of 
diagnostic grade technologies to ensure genetic integrity for a collection of iPSCs and differentiated progeny cells 
from the ForIPS consortium. Of the 72 primary iPSC lines presented here 61 were generated for the core ForIPS 
project (Parkinson’s disease) and 30 of these (49.2%) have been distributed to subprojects for functional analyses 
at the time of the final project report.
We confirm the minimal standard of conventional karyotyping and genetic fingerprinting. G-banded karyo-
typing led to the exclusion of an appreciable proportion of cell lines with numerical chromosomal anomalies, at 
a comparable frequency with other reports36 but also large structural chromosomal rearrangements, which are 
quite frequent in iPSCs (Figs 3A,B and S1; File S2). While this technique is considered relatively cheap, it requires 
a lot of hands-on work and does not produce results in a computable electronic form. CMA analysis for copy 
number aberrations can also identify aneuploidies. However, chromosomal rearrangements in a balanced state 
would be missed (Figs 3C and S1). Some groups perform optical mapping as an alternative screening method14. 
Despite its currently higher costs and the need for specific DNA extraction methods, its higher resolution and 
computational accessibility might make optical mapping a method of choice for structural aberrations. Also, 
genetic fingerprinting proved to be a valuable first line QC step which allowed us to resolve sample mix-ups. 
While short tandem repeat (STR)-based methods, like the one we used, are widely employed for identity testing, 
these do not allow sample tracking in a complete genetic pipeline. A single nucleotide polymorphism based pro-
filing panel for sample tracking37 would likely be more valuable for biobanks.
Our results using high density CMA showed that about 70% of iPSC lines have a detectable somatic CNV 
≥100 kb, independent of the reprogramming method used (Fig. 2A–C). This fraction is higher than in previous 
large reports5,9,38, which can be attributed to variable CMA resolution and differences in filtering and analysis 
between the studies. Indeed, a smaller study using the same CMA platform we chose, did also find CNVs in a 
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relatively large portion of iPSCs39. We could point out several genomic regions affected by recurrent CNVs in 
iPSCs, explainable either by genetic fragility of the locus40 or by proliferative survival advantage41. By applying 
high coverage exome sequencing we identified SNV/indel variants in the coding gene regions in every iPSC line 
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Figure 6. Exome sequencing enables multiple cellular analyses. (A) Box- and scatterplots of the relative 
mitochondrial genome ratio for all samples. Average read coverage for the mitochondrial genome (chrM) was 
normalized to the targeted regions of chromosome 1 (chr1). The level of significance is annotated by asterisks 
or as not significant (NS) (two sided Wilcoxon signed-rank test). Fibroblast (FI) and RiPSC/SiPSC cultures 
show a higher mitochondrial genome dosage than PBLs (BL = blood samples from individuals in this study; BL-
CNT = blood samples from 53 in-house control samples) and compared to NPC cultures. (B) Telomere content 
of all 16 RiPSC samples from the 4 individuals estimated from off-target telomeric reads by two different 
algorithms, telomerecat (upper panel) and telomerehunter (lower panel) plotted vs. the passage number. While 
both plots show a negative correlation of telomere content with higher passage number (telomerecat: Pearson’s 
r = −0.483, R2 = 0.233, p-value = 0.058; telomerehunter: Pearson’s r = −0.251, R2 = 0.062, p-value = 0.349) 
the results are not significant (see also Fig. S5). (C) Comparison of the read coverage profile at the KLF4 
gene locus of different materials from individual “82A” (blood = brown, fibroblast = tan, SiPSC = green, 
RiPSC = blue). The sudden breaks at the exon-intron boundary indicate multiple integrations of a plasmid with 
a KLF4 transcription factor insert which has no introns (see also Fig. S6). (D) Example of a somatic deletion 
in the DLG2 gene called from the exome data of the NPC sample (“p82A-R1-002” = dark blue) and absent in 
the corresponding fibroblast culture (“f82A-X-001” = green). Dots represent target or anti-target coverage 
bins (y-axis = log2 ratio) and the orange line marks the copy number call by the CNVkit algorithm32 for each 
segment. Note that the deletion was only called in the NPC and not in the RiPSC (“i82A-R1-002” = light blue) 
although the deletion had been previously confirmed in both samples by CMA (see also Fig. S6). NS, not 
significant; “***”, 0.001; “**”, 0.01, “*”, 0.05.
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analyzed, independent of the reprogramming method used (Fig. 4A). Interestingly, every primary iPSC line had 
at least one fixed somatic high impact (truncating) SNV/indel and several somatic missense variants of which a 
large portion was predicted as damaging to the protein function by different computational scores (Fig. 5A,B,D). 
Several of the identified somatic variants affect genes implicated in cancer or monogenic diseases as well as genes 
with elevated expression in the brain (Table 1). These findings are well in line with previous reports12. Our results 
suggest a functional impact of certain somatic variants in the iPSC lines. Together with the high variability in 
somatic variant load observed for all variant classes (Figs 2A and 4A), even in isogenic lines, these observations 
signify that each line must be individually assessed before use in downstream experiments or therapeutic applica-
tions. In addition, we found no significant differences between integrating and non-integrating reprogramming 
methods regarding somatic CNVs (Fig. 2A,B) and SNV/indel (Fig. 4A) counts, thus supporting a recent publica-
tion for SNVs/indels14. This information is of special value to researchers working with established RiPSC lines.
The relationship between culture passaging and somatic variants count has been controversially discussed in 
the literature. While early analyses have described a negative correlation between CNV count and passaging42, 
recent studies using low resolution CMA5,12 or whole genome sequencing13 could not confirm this. Furthermore, 
an older study showed an increase in coding SNV counts from 7 to 13 for a single analyzed iPSC line between 
Sample Gene HGVS List OMIM-G OMIM-P Phenotype Inh. pLI
i82A-S1-022 IL1RAPL1 c.1372+1G>T, p.? OMIM, HPA *300206 #300143 Mental retardation, XLR 21/34 XLR 1.00
p82A-R1-001 ADAT3 c.485G>A, p.(Trp162*) OMIM *615302 #615286 Mental retardation, AR 36 AR 0.00
i82A-R1-001 RP1 c.3949C>T, p.(Gln1317*) OMIM *603937 #180100 Retinitis pigmentosa 1 AR, AD 0.00
i82A-S1-022 MMP20 c.1381dupA, p.(Thr461Asnfs*5) OMIM *604629 #612529 Amelogenesis imperfecta, type IIA2 AR 0.00
i82A-R1-001 GPR162 c.747_748delinsTT, p.(Arg250*) HPA na na na na 0.02
i88H-R1-002 BRAF c.981-2A>G, p.? CGC, OMIM *164757
#115150, 
#613707, 
#613706
Cardiofaciocutaneous syndrome; 
LEOPARD syndrome 3; Noonan 
syndrome 7
AD, AD, 
AD 1.00
i88H-R1-002 TWIST2 c.3G>T, p.? OMIM *607556
#200110, 
#209885, 
#227260
Ablepharon-macrostomia 
syndrome; Barber-Say 
syndrome; Focal facial dermal 
dysplasia 3, Setleis type
AD, AD, 
AR 0.44
i88H-R1-002 PAM16 c.285_288del, p.(Ser96Argfs*44) OMIM *614336 #613320 Spondylometaphyseal dysplasia, Megarbane-Dagher-Melike type AR 0.14
i88H-R1-001 CDT1 c.352-1G>A, p.? OMIM *605525 #613804 Meier-Gorlin syndrome 4 AR 0.00
i88H-R1-002 LAMB1 c.869_870del, p.(Val290Glyfs*13) OMIM *150240 #615191 Lissencephaly 5 AR 0.00
i88H-R1-002 MTM1 c.1497del, p.(Trp499Cysfs*3) OMIM *300415 #310400 Myotubular myopathy, XLR XLR 1.00
i88H-R1-001 DOCK2 c.3060_3072+6del, p.? OMIM *603122 #616433 Immunodeficiency 40 AR 1.00
i88H-R1-002 CYP46A1 c.894_897del, p.(Phe299Serfs*16) HPA *604087 na na na 0.75
i88H-R1-002 MCF2 c.541G>T, p.(Glu181*) HPA *311030 na na na 0.94
iAY6-R1-003 GRIK2 c.723+1G>A, p.? OMIM, HPA *138244 #611092 Mental retardation, AR, 6 AR 0.99
iAY6-R1-003 SYNE2 c.4051C>T, p.(Gln1351*) OMIM *608442 #612999 Emery-Dreifuss muscular dystrophy 5 AD 0.00
iAY6-R1-003 C2CD3 c.1726_1730+2delinsC, p.? OMIM *615944 #615948 Orofaciodigital syndrome XIV AR 0.00
iAY6-R1-003 ANKRD11 c.5759_5763delinsG, p.(Thr1920Argfs*42) OMIM *611192 #148050 KBG syndrome AD 1.00
iPX7-R1-001 CARD11 c.214C>T, p.(Arg72*) CGC, OMIM *607210
#616452, 
#615206, 
#617638
B-cell expansion with NFKB and 
T-cell anergy; Immunodeficiency 
11 A; Immunodeficiency 11B
AD, AR, 
AD 1.00
iPX7-R1-001 ALG2 c.32C>A, p.(Ser11*) OMIM *607905 #616228
Myasthenic syndrome, 
congenital, 14, with tubular 
aggregates
AR 0.02
iPX7-S1-004 DNAH5 c.2049del, p.(Gln684Lysfs*7) OMIM *603335 #608644 Ciliary dyskinesia, primary, 3, with or without situs inversus AR 0.00
iPX7-S1-004 ITCH c.540dup, p.(Cys181Leufs*7) OMIM *606409 #613385
Autoimmune disease, 
multisystem, with facial 
dysmorphism
AR 1.00
iPX7-S1-004 VCAN c.2492_2495del, p.(Leu831Glnfs*5) OMIM *118661 #143200 Wagner syndrome 1 AD 1.00
iPX7-S1-004 ARPP21 c.1923T>G, p.(Tyr641*) HPA *605488 na na na 0.00
iPX7-S1-004 WBSCR17 c.1081-1_1081delinsAA, p.? HPA *615137 na na na 0.10
Table 1. Fixed variants with predicted loss-of-function effect in known cancer associated genes according to 
the COSMIC database (CGC), known disease genes (OMIM) or genes highly expressed in the brain according 
to the Human Protein Atlas (HPA). Inh., inheritance mode (“AD”: autosomal dominant, “AR”: autosomal 
recessive, “XLR”: X-linked recessive); HGVS, Human Genome Variation Society nomenclature (“c.”: coding 
DNA change, “p.”: protein change; “p.?”: consequence of the variant at protein level cannot be predicted without 
further functional assays); OMIM-G, OMIM (https://omim.org/) gene number; OMIM-P, OMIM phenotype 
number; CGC, COSMIC cancer gene census56 gene list; HPA, human protein atlas57 brain elevated gene set 
(File S6); pLI, probability of loss-of-function intolerance58; “na”: not available.
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passage 9 and 4043, Our results do not support a strong effect of passaging on either CNV or SNV/indel counts 
(Figs 2E and 4C). The four NPC lines differentiated from RiPSCs in our study showed no additional CNVs 
(Fig. 2A–C) and have not significantly acquired SNVs/indels during differentiation (Fig. 4B). Together, these data 
argue against a strong effect of passage number on somatic variant count.
Based on increasing numbers of somatic CNVs in aging individuals as demonstrated in cancer studies44–46, 
one would expect to find higher frequencies of this mutation type in iPSCs derived from older donors. Our 
results, however, demonstrated no significant correlation between donor age and somatic CNV count, confirm-
ing similar recent reports5,12. In contrast to CNVs, somatic SNV/indel load in exome regions has been shown to 
linearly increase with donor age in iPSCs derived from peripheral blood mononuclear cells12. We also confirm 
this observation in our iPSC sample collection derived from skin fibroblasts (Fig. 4D). Altogether, our find-
ings and the descriptions in the literature point to differences in the mutational mechanisms and cellular pro-
cesses involved in the formation of somatic CNVs and SNVs/indels. Our results point to UV irradiation damage 
related somatic sub-clonality in the parental fibroblasts as a source for SNVs/MNPs and inter-culture variability 
(Figs 4A,D and 5A–C). Recent studies suggest that most variants identified in iPSC, but absent from the donor 
germline, are already present in a subpopulation of the cells of origin12,13,15. We also show extensive somatic mosa-
icism in the parental fibroblast cultures as a source for fixed somatic variants in iPSCs (Fig. 5F). Considering the 
data regarding passaging, we propose that random genetic drift induced by colony picking from poly-/oligoclonal 
cell cultures and not positive selection is a major cause of somatic variation in iPSC clones (Fig. 1C). This model 
is very different from the typical situation in cancer, where few “driver” mutations pose a strong advantage47 in 
an environment of selective pressure, while most “passenger” variants are neutral (Fig. 1C). The goal in iPSC 
research is not to find detrimental driver mutations but to produce intact cells resembling the donor, thus suc-
cessful strategies in cancer and iPSC fields will differ.
Mitochondria are crucial for cellular senescence and pluripotency in iPSCs48. Differences in mitochondrial 
morphology, count49 and mitochondrial DNA (mtDNA) content50,51 during pluripotent stem cell reprogramming 
and differentiation have been reported52. Our analysis of the mitochondrial genome content showed significant 
differences between PBLs, iPSCs and differentiated NPCs, but not between fibroblasts and iPSCs (Fig. 6A). A 
similar method for relative quantification of mtDNA from exome data has recently been compared to gold stand-
ard methods53. These data highlight the added value of high-throughput sequencing reads for complementary 
analyses with potential use in iPSC characterization. The application of our method in large studies will likely 
expand our current knowledge of mitochondrial function in iPSCs and their progeny. Our exemplary attempts 
to telomere content analysis, viral integration and CNV analysis from exome data show that these analyses are in 
principal possible but need further evaluation and calibration (Fig. 6B–D). Albeit applicable to exome data, most 
of the described techniques will likely lead to better results using whole genome sequencing data.
In conclusion, we applied high-resolution diagnostic methods in a systematic pipeline to ensure genetic sta-
bility of iPSCs generated in the ForIPS consortium and confirmed several previous associations in an iPSC col-
lection from diverse donors. Most importantly, we showed that different clones have a high variability regarding 
somatic variant load. Based on our findings, 46/72 (63.9%) primary iPSC lines from the ForIPS study could be 
recommended for research distribution considering karyotype and CMA. This highlights that the genetic evalua-
tion of each individual iPSC clone is fundamental prior to its use as model or for therapeutic purposes. A combi-
nation of karyotyping by optical mapping, CMA and exome sequencing will likely provide the best combination 
regarding cost and efficiency in the next years. From the primary iPSC lines with additional exome sequencing 
presented here, 6/14 (42.9%) could be recommended considering the exclusion of cell lines with a high impact 
(truncating) and fixed variant in genes involved in monogenic diseases, cancer or highly expressed the brain 
(Table 1 and File S1). As even the smallest variant classes can have detrimental effects on important genes, we 
recommend an inspection of all iPSCs based on three pillars: karyotyping for balanced aberrations, CMA for 
CNV detection, and NGS to search for SNVs/indels. Starting with three iPSC lines and considering only karyo-
typing and CMA one would have a chance of ≥90% (binominal probability: 1-(1–0.639)3 ~ 0.953) to end up with 
least one iPSC line passing these two QC steps. However, when also considering exome sequencing one would 
already need eight starting iPSC lines for a chance of ≥90% (binominal probability: 1-(1–0.639 * 0.429)8 ~ 0.923) 
to have at least one iPSC line passing all three QC steps. Ideally these analyses should be performed on the initial 
iPSC cultures in comparison to an independent germline sample to find the best iPSC line before using these for 
experiments and again on later derivatives to ensure validity of functional results before publication. Future work 
will have to determine an optimal cost-benefit ratio in large biobanks.
Methods
Inclusion of subjects in the ForIPS resource. The ForIPS research consortium (http://forips.med.fau.de/) 
has established an institutional iPSC biobank resource to explore diseases of the brain, particularly PD. All 
reported iPSC lines with adequate consent have been registered in hPSCreg54. To exchange selected lines for 
research purposes the scientific board of the UKER biobank will consider each request.
Twenty-three individuals were recruited at the Department of Molecular Neurology (Universitätsklinikum 
Erlangen). All individuals were phenotypically examined by a clinician experienced with neurological dis-
eases. PD patients were diagnosed by board-examined movement disorder specialists according to consensus 
criteria of the German Society of Neurology, which are similar to the UK PD Society Brain Bank criteria for 
diagnosis of PD55. Age at tissue donation, gender, ethnicity and family history were assessed. All participants 
gave written informed consent to the study prior to donating a skin biopsy from a typically sun unexposed area 
of the inner upper arm. From this biopsy, a fibroblast stock culture was created. Four individuals additionally 
donated PBLs for an independent germline DNA sample (Fig. 1A). Symptomatic individuals had targeted genetic 
testing to exclude or confirm monogenic forms of PD, HSP and ID (see Supplementary information). Study 
approval including all iPSC procedures was granted by the local ethics committees (No. 4485 and 4120, FAU 
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Erlangen-Nuernberg, Germany; and No StV I 1/09 Canton of Zurich) and all participants or their legal guardians 
gave written informed consent prior to inclusion into the study. All related experiments and methods were per-
formed in accordance with relevant guidelines and regulations.
Reprogramming, differentiation, culture conditions and genetic QC. Detailed methods used for 
generation of iPSC, differentiation of NPCs, cell culture conditions and for the genetic QC analyses performed are 
described in the Supplementary information.
Data Availability
The consent and ethics approval for the ForIPS study does not cover the deposition of identifiable germline 
genomic data of study participants into public repositories. We follow the DFG (German Research Foundation) 
recommendations for safeguarding good scientific practice and thus internally archive all data for this study. We 
provide file checksums for all primary array and sequencing data (File S2). These shall be accessible for any legit-
imate request from the corresponding author (A.Re.). With future consent updates we plan to submit this genetic 
data to public repositories.
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